|
Market Closed -
Nasdaq
16:00:00 2026-10-01 EDT
|
5-day change | 1st Jan Change | ||
| 11.33 USD | -7.96% |
|
-5.43% | +200.53% |
| 09-14 | Top Premarket Decliners | MT |
| 08-31 | Social Buzz: Wallstreetbets Stocks Mixed Premarket Monday; SELLAS Life Sciences to Advance, Tesla to Decline | MT |
Company Valuation: SELLAS Life Sciences Group, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 87.85 | 48.59 | 33.99 | 73.2 | 537 | 2,288 | - | - |
| Change | - | -44.69% | -30.05% | 115.37% | 633.64% | 326.07% | - | - |
| Enterprise Value (EV) | 87.85 | 48.59 | 33.99 | 73.2 | 537 | 2,288 | 2,288 | 2,288 |
| Change | - | -44.69% | -30.05% | 115.37% | 633.64% | 326.07% | 0% | 0% |
| P/E | -4.13x | -1.11x | -0.79x | -2.08x | -15.1x | -55.3x | -119x | 324x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0x | 0x | 0x | 0.3x | 3.1x | 2.2x | -2x |
| Capitalization / Revenue | 11.6x | 48.6x | - | - | - | - | 43.1x | 18.7x |
| EV / Revenue | 0x | 0x | - | - | - | - | 43.1x | 18.7x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -56.1x | -89.8x | -701x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.34 | -2.13 | -1.34 | -0.5 | -0.25 | -0.205 | -0.095 | 0.035 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 7.6 | 1 | - | - | - | - | 53.09 | 122 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -25.29 | -41.95 | -37.87 | -31.51 | -28.27 | -40.79 | -25.48 | -3.266 |
| Net income 1 | -20.7 | -41.3 | -37.34 | -30.88 | -26.86 | -38.3 | -21.38 | 2.984 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 5.53 | 2.36 | 1.06 | 1.04 | 3.77 | 11.33 | 11.33 | 11.33 |
| Nbr of stocks (in thousands) | 15,886 | 20,588 | 32,062 | 70,382 | 142,442 | 201,946 | - | - |
| Announcement Date | 3/31/22 | 3/16/23 | 3/28/24 | 3/20/25 | 3/19/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -55.27x | - | - | - | 2.29B | |
| 21.73x | 7.77x | 15.61x | 1.37% | 74.41B | |
| 30.79x | 8.87x | 27.62x | 0.04% | 59.26B | |
| 32.79x | 5.89x | 17.64x | 0.99% | 47.14B | |
| 33.58x | 3.26x | 14.07x | -.--% | 42.91B | |
| -21.23x | 229.92x | -22.88x | -.--% | 44.13B | |
| 46.86x | 5.42x | 29.73x | -.--% | 40.79B | |
| 27.79x | 7.97x | 20.59x | 0.41% | 30.77B | |
| 33.94x | 7.26x | 18.84x | -.--% | 29.31B | |
| -66.62x | 12.77x | -65.09x | -.--% | 23.71B | |
| Average | 8.44x | 32.13x | 6.24x | 0.31% | 39.47B | |
| Weighted average by Cap. | 19.12x | 32.23x | 10.39x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SLS Stock
- Valuation SELLAS Life Sciences Group, Inc.
Select your edition
All financial news and data tailored to specific country editions
